共 150 条
[1]
Kazandjian D(2016)Multiple myeloma epidemiology and survival: a unique malignancy Semin Oncol 43 676-681
[2]
Cavo M(2017)Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group Lancet Oncol 18 e206-e217
[3]
Terpos E(2020)Role of imaging in multiple myeloma Am J Hematol 17 e328-e346
[4]
Nanni C(2016)International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Lancet Oncol 130 30-34
[5]
Moreau P(2017)Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma Blood 37 1083-1088
[6]
Lentzsch S(2013)CXCR4 is a good survival prognostic indicator in multiple myeloma patients Leuk Res 5 618-630
[7]
Zweegman S(2015)Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging Theranostics 47 537-546
[8]
Baffour FI(2020)Chemokine receptor-4 targeted PET/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET/CT Eur J Nucl Med Mol Imaging 7 205-212
[9]
Glazebrook KN(2017)[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values Theranostics 32 503-511
[10]
Kumar SK(2018)CXCR4-directed theranostics in oncology and inflammation Ann Nucl Med 7 1589-1597